Strengths of this study include the prospective design, with the accuracy of data collection according to systematic protocol-specified visits at baseline, 3 and 6 months and the enrolment of a very selected study population including only patients with RA, PsA or axSpA who were switched to GLM after previous failure with another anti-TNFα. The gene discussed is TNF; the disease is rheumatoid arthritis.